The Association of Statin Therapy with the Risk of Recurrent Venous Thrombosis.

Publication Type:

Journal Article

Source:

Journal of thrombosis and haemostasis : JTH (2016)

Abstract:

BACKGROUND: Meta-analyses of randomized controlled trials suggest that treatment with HMG-CoA reductase inhibitors (statins) lowers the risk of incident venous thrombosis (VT), particularly among those without prevalent clinical cardiovascular disease (CVD). Whether this is true for the prevention of recurrent VT is debated. We used an observational inception cohort to estimate the association of current statin use with the risk of recurrent VT.

METHODS AND RESULTS: The study setting was a large healthcare organization with detailed medical record and pharmacy information at cohort entry and throughout follow-up. We followed 2,798 subjects 18-89 years of age who experienced a validated incident VT between January 1, 2002 and December 31, 2010, for a first recurrent VT, validated by medical record review. During follow-up, 457 (16%) developed a first recurrent VT. In time-to-event models incorporating time-varying statin use and adjusting for potential confounders, current statin use was associated with a 26% lower risk of recurrent VT: HR=0.74; 95%CI: 0.59-0.94. Among cohort members free of CVD (n=2,134), current statin use was also associated with a lower risk (38%) of recurrent VT: HR=0.62; 95%CI: 0.45-0.85. We found similar results when restricting to new users of statins and in subgroups of different statin types and doses.

CONCLUSIONS: In a population-based cohort of subjects who had experienced an incident VT, statin use, compared with non-use, was associated with a clinically-relevant lower risk of recurrent VT. These findings suggest a potential secondary benefit of statins among patients who have experienced an incident VT. This article is protected by copyright. All rights reserved.